diagnosis
The diagnosis should be made from an endoscopic biopsy with the histology to be given according to the WHO criteria. Smallcell carcinomas must be identified and separated from squamous cell carcinomas and adenocarcinomas and be treated accordingly.
staging
Staging should include clinical examination, blood counts, liver and renal function tests, endoscopy (including upperaerodigestive tract endoscopy in case of squamous cell carcinoma), and a CT scan of chest and abdomen. In candidates for surgical resection, esophagogram and endoscopic ultrasound have to be added to evaluate the T (and N) stage of the tumor and to assist in the planning of the surgical procedure [II, B] . When available, positron emission tomography (PET) may be helpful in identifiying otherwise undetected distant metastases or in diagnosis of suspected recurrence [II, B] .
In locally advanced (T3/T4) adenocarcinomas of the esophago-gastric junction infiltrating the anatomic cardia, laparoscopy can rule out peritoneal metastases [II, B] .
For selection of local treatments the tumors should be assigned to the cervical or intrathoracic esophagus or to the esophago-gastric junction [IV, C].
The stage is to be given according to the tumor-nodemetastasis system with corresponding American Joint Committee on Cancer stage grouping (see table) .
treatment
Primary interdisciplinary planning of the treatment is mandatory. Surgery is regarded as standard treatment only in carefully selected operable patients with localized tumors. Transthoracic esophagectomy with two-field resection is recommended for intrathoracic squamous cell carcinoma [III, C] . No standard treatment can be defined for carcinomas of the cervical esophagus. The extent of surgery in adenocarcinomas is still a matter of debate.
Preoperative (with and without postoperative) radiation does not add any survival benefit to surgery alone [I, A]. This treatment is not recommended.
Although meta-analyses and one recent phase III trial suggested that preoperative chemoradiation confers a survival benefit,, it is not clear which patients (stage, tumor location, histology) will most benefit from this preoperative treatment [I, B] and postoperative mortality appears to be increased.
Evidence for clinical benefit from preoperative chemotherapy exists for adenocarcinoma. Patients with adenocarcinomas of the lower esophagus/esophago-gastric junction may be managed with pre-and postoperative chemotherapy [I, B] .
Data on adjuvant chemo(radio)therapy are limited, except for lower esophageal/ esophago-gastric junction adenocarcinomas after limited surgery.
treatment of limited disease (Tis-T2 N0-1 M0)
Surgery is the treatment of choice in early cancer (Tis-T1a N0). Endoscopic mucosal resection is under investigation.
Surgery is regarded as standard treatment of localized SCC (T1-2 N0-1), although long-term survival does not exceed 25% if regional lymph nodes are involved.
For patients unable or unwilling to undergo surgery, combined chemoradiation is superior to radiotherapy alone [I, A].
Pre-operative chemotherapy is considered as a standard treatment option for localised AC. Surgery alone is not a standard treatment in these stages since even in M0 cases a complete tumor resection is not possible in 30% (pT3) and 50% (pT4) of the tumors. Furthermore, even after complete tumor resection long-term survival rarely exceeds 20%.
squamous cell carcinoma
Patients with locally advanced disease may benefit from preoperative chemotherapy or, particularly, preoperative chemoradiation, while increasing the rates of complete tumor resection, improving local tumor control and thereby improving survival in phase III trials [II, B] . It is suggested, however, that preoperative chemoradiation may increase postoperative mortality. Owing to its high complete response rate, chemoradiation with close surveillance and salvage surgery for relapse may be considered as a definitive treatment for locally advanced disease (particularly in the upper third of the oesophagus), as supported by recent results of a French (FFCD 9102) and a German (Stahl 2005 
It is a matter of debate whether radiation adds to the survival benefit compared with preoperative chemotherapy alone and which patients may not benefit from surgery.
Nevertheless, cisplatin/5-FU combined with 40 Gy followed by surgery can be regarded as an option in these tumors [II, B] .
Patients with metastatic esophageal cancer can be considered for different options of palliative treatment depending on the clinical situation. Single-dose brachytherapy may be a preferred option, since it provides better long-term relief of dysphagia with fewer complications than metal stent placement [I, B] .
Chemotherapy is indicated for palliative treatment in selected patients [III, B] .
response evaluation
Response is routinely evaluated by symptomatic evolution, esophagogram, endoscopy (with biopsies) and CT scan.
follow-up
Except for those patients that may be candidates to salvage surgery after definitive chemoradiation, there is no evidence that regular follow-up after initial therapy may influence the outcome. Follow-up visits should be concentrated on symptoms, nutrition and psycho-social problems [IV, D] . Tis  N0  M0  Stage I  T1  N0  M0  Stage IIA  T2, T3  N0  M0  Stage IIB  T1, T2  N1  M0  Stage III  T3  N1  M0  T4  Any N  M0  Stage IVA  Any T  Any N  M1a  Stage IVB any T Any N M1b
